Perceive Biotherapeutics is a clinical stage company developing novel drugs and gene therapies for ocular diseases.
Perceive’s lead program for age-related macular degeneration (AMD) is a gene therapy delivering an engineered, protective complement factor transgene to genetically defined patients at risk of developing both dry and wet AMD. Perceive’s second program is a neuroprotective gene therapy aimed at slowing vision loss in a variety of disease instances, with the primary indication being glaucoma. Catalio Venture Partner Eugene De Juan is the company’s CSO.
Perceive’s lead program for age-related macular degeneration (AMD) is a gene therapy delivering an engineered, protective complement factor transgene to genetically defined patients at risk of developing both dry and wet AMD. Perceive’s second program is a neuroprotective gene therapy aimed at slowing vision loss in a variety of disease instances, with the primary indication being glaucoma. Catalio Venture Partner Eugene De Juan is the company’s CSO.
Total raised: $78M
Investors 3
| Date | Name | Website |
| 03.06.2022 | Johns Hopk... | ventures.j... |
| - | Catalio Ca... | cataliocap... |
| - | Retinal De... | retinaldeg... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.01.2023 | Series B | $78M | Johnson &a... |
Mentions in press and media 5
| Date | Title | Description |
| 09.01.2023 | Perceive Biotherapeutics raises USD 78 million in Series B investment from the Retinal Degeneration Fund | RALEIGH, North Carolina, Jan. 6, 2023 — The RD Fund (Retinal Degeneration Fund), the Foundation Fighting Blindness’ venture arm, announces an equity investment in Perceive Biotherapeutics (Perceive Bio), a biotechnology company developing n... |
| 06.01.2023 | Perceive Biotherapeutics Closes $78M in Series B Funding | Perceive Biotherapeutics, a San Francisco, CA-based biotech company focused on technologies and therapeutics in ophthalmology, raised $78M in Series B funding. The round was led by Johnson & Johnson Innovation – JJDC, Inc.(JJDC), with p... |
| 06.01.2023 | Biotech startup Perceive Bio closes $78M in Series B funding led by Johnson & Johnson to prevent the largest causes of irreversible blindness | TL;DR Perceive Biotherapeutics, a Silicon Valley biotech tech startup focused on technologies and therapeutics in ophthalmology, has raised $78M in Series B funding led by Johnson & Johnson Innovation. Using decades of academic research... |
| 05.01.2023 | Perceive Biotherapeutics Grabs $78M Series B | SOUTH SAN FRANCISCO, CA, Perceive Biotherapeutics today announced the closing of a $78 million Series B funding round. >> Click here for more funding data on Perceive Biotherapeutics >> To export Perceive Biotherapeutics fun... |
| - | Perceive Biotherapeutics | - |